RECRUITING

Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Postural tachycardia syndrome (POTS) is the most common chronic cause of postural lightheadedness, and upright confusion afflicting many Americans, mostly young women. Many POTS patients hyperventilate by increasing their depth of breathing that produces tachycardia, alters blood flow and blood pooling in the body and importantly reduces brain blood flow causing "brain fog". In this proposal the investigators will demonstrate in young women that abnormal repeated brief impairment of blood pressure and brain flow just after standing sensitizes the body's oxygen sensor in POTS to respond as if it were in a low oxygen environment causing hyperventilation and its consequences. In this project the investigators will use various drugs that will help to understand the mechanisms that cause POTS in this unique subset of POTS patients who hyperventilate.

Official Title

Mechanism of Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome in POTS Patients With Orthostatic Hyperpnea and Hypocapnia

Quick Facts

Study Start:2022-09-23
Study Completion:2024-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05923840

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 39 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * The investigators will recruit female POTS cases (N=80) and healthy female control subjects (N=40) aged 15-39 years, matched for BMI. POTS is a disease in which 80-90% are females. Therefore, the investigators will only recruit female POTS patients and controls.
  1. * Any subjects with systemic disease or who cannot stop taking prescribed medications for at least 2 weeks prior to study.

Contacts and Locations

Study Contact

Marvin S Medow, Ph.D.
CONTACT
914-594-2848
marvin_medow@nymc.edu
Julian M Stewart, M.D., Ph.D.
CONTACT
914-594-2849
julian_stewart@nymc.edu

Principal Investigator

Marvin S Medow, Ph.D.
PRINCIPAL_INVESTIGATOR
New York Medical College

Study Locations (Sites)

NewYork Medical College
Hawthorne, New York, 10532
United States

Collaborators and Investigators

Sponsor: New York Medical College

  • Marvin S Medow, Ph.D., PRINCIPAL_INVESTIGATOR, New York Medical College

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-23
Study Completion Date2024-08-31

Study Record Updates

Study Start Date2022-09-23
Study Completion Date2024-08-31

Terms related to this study

Keywords Provided by Researchers

  • Postural Tachycardia Syndrome (POTS)
  • Young Females
  • Tilt Table Testing
  • Initial Orthostatic Intolerance

Additional Relevant MeSH Terms

  • Postural Orthostatic Tachycardia Syndrome
  • Hypocapnia
  • Hyperventilation